This article may contain affiliate links. We may earn a commission if you make a purchase through these links, at no extra cost to you.

Next-Gen GLP-1 Drugs in the Pipeline: What's Coming After Ozempic and Mounjaro

Quick Answer

• Orforglipron (Eli Lilly) is an oral GLP-1 pill that can be taken any time of day without food restrictions — FDA decision expected in mid-2026, with Phase 3 trials showing 10.5% body weight loss
• Retatrutide (Eli Lilly) is a first-in-class triple agonist (GLP-1/GIP/glucagon) that produced a record-breaking 28.7% weight loss in Phase 3 — the most of any obesity drug ever tested — with a potential launch in 2028
• CagriSema (Novo Nordisk) combines semaglutide with an amylin analog and showed 22.7% weight loss at 68 weeks — regulatory filing planned for 2026 with a U.S. launch expected in 2027
• Amycretin (Novo Nordisk) is an oral GLP-1/amylin dual agonist that produced 22% weight loss in just 36 weeks in early trials — now entering Phase 3 in 2026

---

The GLP-1 Revolution Is Just Getting Started

Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have transformed the weight-loss landscape, with millions of patients now using these medications worldwide. But the pharmaceutical industry is far from done. The next generation of obesity drugs promises even greater weight loss, more convenient oral options, and entirely new mechanisms of action.

The obesity drug market is projected to reach $150 billion by 2035 (Clarivate, 2025), and the companies racing to capture this market are investing billions in clinical trials for drugs that could make today's GLP-1 medications look like first drafts.

Here is everything you need to know about the most promising drugs in the pipeline — what they are, how they work differently from current medications, and when they might be available.

If you are currently considering treatment with today's available medications, our guide to the best GLP-1 medications in 2026 covers what is on the market right now.

---

Orforglipron (Eli Lilly) — The Game-Changing Daily Pill

What It Is

Orforglipron is an oral GLP-1 receptor agonist being developed by Eli Lilly, originally licensed from Chugai Pharmaceutical in 2018. Unlike current oral GLP-1 options (like the Wegovy pill or Rybelsus), orforglipron is a small molecule rather than a peptide — and this distinction has enormous practical implications.

Why It Matters

Current oral semaglutide (the Wegovy pill and Rybelsus) requires patients to take it on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating or drinking anything else. These restrictions exist because the peptide-based medication is fragile and poorly absorbed.

Orforglipron eliminates these restrictions entirely. Because it is a small molecule rather than a peptide, it can be taken any time of day, with or without food, with no water restrictions. For patients who find injection needles or strict dosing schedules inconvenient, this is a major step forward.

Clinical Trial Results

ATTAIN-2 Trial (Phase 3, 2025):

• Participants taking the highest dose of orforglipron lost an average of 22.9 lbs (10.5% body weight) at 72 weeks
• The trial enrolled adults with obesity or overweight with at least one weight-related condition

ACHIEVE-3 Trial (Phase 3 — Diabetes, 2025):

• Orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg
• Participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg
• This head-to-head comparison with oral semaglutide showed orforglipron's superiority in both weight loss and blood sugar control

ATTAIN-MAINTAIN Trial (Phase 3, 2025):

• Demonstrated strong weight maintenance after initial weight loss — patients who continued orforglipron maintained their results, while those switched to placebo regained weight

Earlier Phase 2 Results:

• Patients lost 8.6% to 12.6% of body weight (19.8 to 29.3 pounds) after just 26 weeks, compared to 2% (4.6 pounds) with placebo

FDA Timeline

Orforglipron was selected for the FDA's National Priority Review Voucher pilot program in 2025, signaling the agency considers it a high-priority medication. The FDA decision is expected in mid-2026 for the obesity indication.

Side Effects

The side effect profile is similar to other GLP-1 medications — primarily gastrointestinal (nausea, vomiting, diarrhea). In trials, GI side effects were generally mild to moderate and decreased over time.

The Bottom Line

Orforglipron is likely to be the first truly convenient oral GLP-1 medication for weight loss. While its weight-loss percentage (10.5%) is lower than injectable Wegovy (14.9%) or Zepbound (20.9%), the no-restriction oral format could make GLP-1 therapy accessible to millions of patients who resist injections. If you want to understand how current oral vs. injectable options compare, see our Wegovy pill vs. injection breakdown.

---

Retatrutide (Eli Lilly) — The Triple Threat

What It Is

Retatrutide is a first-in-class triple hormone receptor agonist that targets three different receptors simultaneously: GLP-1, GIP, and glucagon. While tirzepatide (Zepbound/Mounjaro) was groundbreaking as a dual agonist (GLP-1/GIP), retatrutide adds a third target — glucagon — creating an entirely new class of obesity treatment.

Why It Matters

Each receptor contributes to weight loss through different mechanisms:

• GLP-1 receptor: Reduces appetite, slows gastric emptying, improves blood sugar
• GIP receptor: Enhances insulin secretion, improves fat metabolism, may help reduce nausea
• Glucagon receptor: Increases energy expenditure, promotes fat burning in the liver, reduces fat storage

The addition of the glucagon receptor is what sets retatrutide apart. Glucagon is traditionally known as a hormone that raises blood sugar, but at the right balance, it also increases the number of calories your body burns — essentially boosting your metabolic rate. This is why retatrutide is producing weight loss numbers that rival bariatric surgery.

Clinical Trial Results

TRIUMPH-4 Trial (Phase 3, December 2025):

This was the first successful Phase 3 trial for retatrutide, conducted in adults with obesity or overweight and knee osteoarthritis. The results were remarkable:

• Retatrutide 9 mg: Average weight loss of 26.4% (29.1 kg / 64.2 lbs)
• Retatrutide 12 mg: Average weight loss of 28.7% (32.3 kg / 71.2 lbs)
• Placebo: Weight loss of 2.1%

To put this in perspective — for a 250-pound person, the 12 mg dose would produce an average loss of approximately 72 pounds. This is the most weight loss ever recorded in a Phase 3 obesity drug trial.

Additional Benefits:

• Significant improvements in osteoarthritis pain (WOMAC pain subscale: -4.4 to -4.5 points vs. -2.4 for placebo)
• Reductions in cardiovascular risk markers, including non-HDL cholesterol and systolic blood pressure
• Improvements in physical function and mobility

Earlier Phase 2 Results (2023):

• At the highest dose (12 mg), patients lost up to 24.2% of body weight at 48 weeks
• 100% of participants in the 12 mg group lost at least 5% of their body weight
• 93% lost at least 10%
• 75% lost at least 15%

Safety Concerns

A new safety signal emerged in the TRIUMPH-4 data: dysesthesia (abnormal sensations like tingling, burning, or prickling) was reported in 8.8% of patients on the 9 mg dose and 20.9% on the 12 mg dose, compared to just 0.7% on placebo. This dose-dependent side effect will be closely monitored in upcoming trials. Otherwise, the GI side effect profile was similar to other GLP-1 medications.

FDA Timeline

Seven additional Phase 3 trials are expected to complete throughout 2026, evaluating retatrutide across obesity and type 2 diabetes populations. These include a maintenance dose of 4 mg in addition to the 9 mg and 12 mg doses. Clarivate projects a potential U.S. launch in 2028.

The Bottom Line

Retatrutide has the potential to redefine obesity treatment. Nearly 29% average weight loss approaches the results of gastric bypass surgery (typically 25–35%) without any surgical intervention. However, the dysesthesia signal and the need for additional Phase 3 data mean it is still several years from market. If approved, it could become the most effective pharmaceutical weight-loss treatment ever developed.

---

CagriSema (Novo Nordisk) — Semaglutide's Powerful Upgrade

What It Is

CagriSema is a fixed-ratio combination of two medications:

1. Semaglutide — the same GLP-1 receptor agonist found in Wegovy and Ozempic
2. Cagrilintide — a long-acting amylin analog

Both are combined into a single weekly injection, so patients get the benefits of both drugs with one shot.

Why It Matters

Amylin is a hormone naturally produced by the pancreas alongside insulin. It works differently from GLP-1:

• Slows gastric emptying through a separate pathway from GLP-1
• Reduces glucagon secretion (the hormone that raises blood sugar)
• Acts on the brain's reward centers to reduce food cravings
• Complements GLP-1 without simply duplicating its effects

By combining semaglutide with an amylin analog, CagriSema attacks obesity through more pathways than semaglutide alone — and the clinical results show it.

Clinical Trial Results

REDEFINE-2 Trial (Phase 3a, published in NEJM, 2025):

• CagriSema produced a mean weight loss of 22.7% at 68 weeks in the primary efficacy analysis
• This significantly exceeded semaglutide alone (approximately 15.8% in comparable trials)
• The trial enrolled adults with obesity or overweight with at least one weight-related condition

Key Comparison:

• CagriSema (22.7%) vs. Wegovy alone (~15%) represents roughly a 50% improvement in weight loss from adding the amylin analog component
• Consistent results across subgroups (age, sex, baseline BMI, race/ethnicity)

Side Effects

The side effect profile is largely consistent with semaglutide alone — primarily gastrointestinal (nausea, vomiting, diarrhea). The addition of cagrilintide did not appear to introduce significant new safety concerns beyond what is expected with GLP-1 medications.

FDA Timeline

Novo Nordisk plans to file for regulatory approval in 2026, with a timeline adjustment to ensure supply chain readiness. A U.S. market launch is expected in 2027. Given that CagriSema uses semaglutide (which already has extensive FDA-approved use), the regulatory pathway may be relatively straightforward.

The Bottom Line

CagriSema represents the most direct upgrade to current Wegovy therapy. For patients already taking semaglutide who want better results, CagriSema could offer a roughly 50% improvement in weight loss with a similar side-effect profile and the same once-weekly injection format. It is Novo Nordisk's answer to the competitive threat from tirzepatide and the next-generation drugs from Eli Lilly.

---

Amycretin (Novo Nordisk) — The Oral Dual Agonist

What It Is

Amycretin is a unimolecular dual agonist of the GLP-1 and amylin receptors developed by Novo Nordisk. Unlike CagriSema (which combines two separate molecules), amycretin is a single molecule designed to activate both receptor types simultaneously.

Why It Matters

Amycretin is exciting for two reasons:

1. Exceptional early weight-loss data — 22% weight loss in just 36 weeks in early trials, which is faster than anything seen with current GLP-1 medications
2. Available in both injectable and oral forms — the oral version showed 10.1% weight loss in diabetes patients at 36 weeks, with the potential for much more at higher doses and longer treatment

The oral formulation is particularly significant. If amycretin can deliver 20%+ weight loss as a daily pill, it could combine the convenience of orforglipron with the efficacy of injectable drugs.

Clinical Trial Results

Phase 2 Trial in Type 2 Diabetes (November 2025):

• Weekly injectable amycretin: weight loss of up to 14.5% at 36 weeks
• Daily oral amycretin: weight loss of up to 10.1% at 36 weeks
• HbA1c reductions: up to 89.1% of patients achieved HbA1c below 7%
• Both formulations showed a safe and well-tolerated profile

Phase 1 Results in Obesity (Published in The Lancet, 2025):

• Amycretin produced approximately 22% weight loss in 36 weeks in early-stage obesity trials
• This result was described as "sparking renewed optimism" for dual amylin/GLP-1 therapy
• The short treatment duration makes this especially impressive — current medications typically take 52–72 weeks to reach peak weight loss

Safety Profile

Both subcutaneous and oral amycretin appeared safe and well-tolerated, with the most common adverse events being gastrointestinal (consistent with other incretin and amylin-based therapies). The vast majority of side effects were mild to moderate in severity.

FDA Timeline

Novo Nordisk plans to initiate Phase 3 trials for amycretin in Q1 2026 for both obesity and type 2 diabetes. Given the typical timeline for Phase 3 obesity trials (1–2 years for enrollment and follow-up, plus regulatory review), a U.S. launch could come as early as 2029–2030.

The Bottom Line

Amycretin may be the most promising early-stage obesity drug in development. Its 22% weight loss in just 36 weeks could translate to 25–30%+ weight loss at a full 72-week treatment duration, potentially rivaling retatrutide. The oral formulation adds convenience, and Novo Nordisk's deep experience with GLP-1 medications supports efficient development. The main drawback is the timeline — Phase 3 trials are just beginning, so patients will need to wait several years.

---

Survodutide (Boehringer Ingelheim) — The Glucagon/GLP-1 Dual Agonist

What It Is

Survodutide is a dual agonist of the glucagon and GLP-1 receptors being developed by Boehringer Ingelheim. While tirzepatide targets GLP-1 and GIP, survodutide takes a different approach by pairing GLP-1 with glucagon receptor activation.

Why It Matters

The glucagon receptor component is what makes survodutide unique among the dual agonists currently in development. Glucagon receptor activation:

• Increases energy expenditure — your body burns more calories at rest
• Promotes fat burning in the liver — particularly important for patients with non-alcoholic fatty liver disease (NAFLD/MASH)
• Reduces liver fat — Phase 2 data showed dramatic reductions in liver fat content

This makes survodutide particularly interesting for patients with both obesity and liver disease, which frequently co-occur.

Clinical Trial Results

Phase 2 Trial in Obesity (2024):

• Survodutide produced weight loss of approximately 18.7% at 46 weeks at the highest dose
• This is comparable to semaglutide 2.4 mg (Wegovy) and positions survodutide competitively in the market

Phase 2 Trial in MASH/NAFLD (2024):

• Survodutide showed remarkable effects on liver disease, with significant reductions in liver fat content
• This dual indication (obesity + liver disease) could be a key differentiator

SYNCHRONIZE Phase 3 Program (Ongoing):

• Multiple Phase 3 trials are currently enrolling or ongoing
• The SYNCHRONIZE program includes studies in overweight/obesity, type 2 diabetes, and MASH
• Results are expected throughout 2026–2027

Side Effects

The side effect profile includes gastrointestinal symptoms common to all GLP-1-class medications. There have also been reports of increased heart rate, which is being monitored in Phase 3 trials.

FDA Timeline

With Phase 3 trials ongoing through 2026–2027, a potential FDA approval could come in 2028–2029. However, the liver disease indication could provide an additional pathway to market if the MASH data is strong.

The Bottom Line

Survodutide's niche may be patients with obesity and co-existing liver disease, where the glucagon component provides unique benefits. Its weight-loss efficacy (~19%) is competitive but not class-leading compared to retatrutide (~29%) or CagriSema (~23%). Its strongest play may be as a specialized treatment for the growing population of patients with both obesity and MASH/NAFLD.

---

MariTide (Amgen) — The Monthly Injection

What It Is

MariTide (maridebart cafraglutide) is Amgen's novel anti-obesity drug that combines an anti-GIPR antibody with a GLP-1 peptide. It is designed for once-monthly subcutaneous injection, which would be the longest-acting obesity medication on the market.

Why It Matters

While most current GLP-1 medications require weekly injections (or daily pills), MariTide's monthly dosing schedule could dramatically improve convenience and adherence. Missing doses is a leading cause of reduced effectiveness with current treatments.

Clinical Trial Results

• Phase 2 data showed weight loss exceeding 24% — rivaling or surpassing bariatric surgery results
• The monthly dosing format showed sustained drug levels throughout the dosing interval
• Phase 3 trials are ongoing with results expected in 2026–2027

FDA Timeline

If Phase 3 results are positive, an FDA filing could happen in 2027–2028, with potential market launch in 2028–2029.

The Bottom Line

MariTide's monthly dosing is its key differentiator. If it delivers on its Phase 2 promise of 24%+ weight loss with just 12 injections per year, it could be highly attractive to patients who prefer minimal treatment burden.

---

Other Notable Pipeline Candidates

Beyond the six major drugs profiled above, several other companies are developing next-generation obesity treatments worth tracking.

Pemvidutide (Altimmune)

Pemvidutide is a GLP-1/glucagon dual agonist similar in concept to survodutide. In Phase 2 trials, it produced approximately 15.6% weight loss at 48 weeks. Altimmune is positioning pemvidutide for both obesity and MASH, with Phase 2b liver data showing significant reductions in liver fat. The company is preparing for Phase 3 trials.

Ecnoglutide (Sciwind Biosciences)

Ecnoglutide is a long-acting GLP-1 receptor agonist being developed by a Chinese biotech company. In Phase 2 trials, it showed weight loss of approximately 16.6% at 24 weeks — notable for the relatively short treatment duration. It is primarily in development for the Chinese and global markets.

Danuglipron (Pfizer)

Pfizer's oral GLP-1 receptor agonist had a turbulent development path. An earlier twice-daily formulation showed significant side effects and tolerability issues. Pfizer has since reformulated danuglipron as a once-daily pill and is evaluating it in Phase 2b trials. Given Pfizer's scale and distribution capabilities, a successful reformulation could make it a significant competitor, but the drug is behind orforglipron in development.

Bimagrumab + Semaglutide (Versanis/Eli Lilly)

A different approach entirely — bimagrumab is an anti-activin type II receptor antibody that promotes muscle growth while reducing fat. When combined with semaglutide, early data showed that patients lost fat while preserving or even gaining muscle mass. This addresses one of the biggest concerns with current GLP-1 medications. Eli Lilly acquired Versanis in 2023, and Phase 3 trials are planned.

---

How Next-Gen Drugs Compare

Drug	Company	Mechanism	Weight Loss	Format	Expected Availability
Orforglipron	Eli Lilly	GLP-1	~10.5%	Daily pill (no restrictions)	Mid-2026 (FDA decision)
CagriSema	Novo Nordisk	GLP-1 + Amylin	~22.7%	Weekly injection	2027
Retatrutide	Eli Lilly	GLP-1/GIP/Glucagon	~28.7%	Weekly injection	2028
Survodutide	Boehringer Ingelheim	GLP-1/Glucagon	~18.7%	Weekly injection	2028–2029
Amycretin	Novo Nordisk	GLP-1 + Amylin	~22% (36 wk)	Pill or injection	2029–2030
MariTide	Amgen	Anti-GIPR + GLP-1	~24%+	Monthly injection	2028–2029

Weight loss percentages from the most recent clinical trial data. Trial durations and populations vary — direct comparisons should be made cautiously.

For context, here is how current medications compare:

Current Drug	Weight Loss	Format
Wegovy (semaglutide 2.4 mg)	~14.9%	Weekly injection
Zepbound (tirzepatide 15 mg)	~20.9%	Weekly injection
Wegovy pill (oral semaglutide)	~15%	Daily pill (with restrictions)
Saxenda (liraglutide 3 mg)	~8%	Daily injection

---

What This Means for Patients Today

If you are considering GLP-1 medication now, these pipeline drugs raise an obvious question: should you wait?

Reasons Not to Wait

• Today's medications are highly effective. Wegovy and Zepbound produce 15–21% average weight loss — life-changing results for most patients. See our guide to how to get a GLP-1 prescription online.
• Obesity is a health emergency. The metabolic, cardiovascular, and joint damage from carrying excess weight compounds over time. Every month of delay has health consequences.
• Pipeline timelines are uncertain. Drug development is unpredictable — FDA decisions can be delayed, safety signals can emerge, and manufacturing challenges can push back launch dates.
• You can always switch later. Starting a GLP-1 medication now does not lock you in. When next-gen options become available, your doctor can help you transition if they offer meaningful advantages for your situation.

Reasons to Stay Informed

• Next-gen drugs may offer better results. If you have tried semaglutide or tirzepatide and plateaued, drugs like retatrutide or CagriSema could provide additional weight loss.
• Oral options are improving. If needles are a barrier, orforglipron (no food restrictions) and oral amycretin could be worth waiting for.
• Costs may decrease. More competition in the market tends to drive prices down. Medicare negotiations and the Medicare GLP-1 Bridge program are already reducing costs for some patients. See our GLP-1 medication cost guide for current pricing strategies.
• Combination therapies may unlock new possibilities. Drugs like CagriSema suggest that combining mechanisms produces better results than single agents alone.

---

The Bigger Picture: Where Obesity Treatment Is Heading

The next-generation drug pipeline signals a fundamental shift in how medicine views and treats obesity.

From Single Target to Multi-Target

The progression from liraglutide (GLP-1 only) to tirzepatide (GLP-1/GIP) to retatrutide (GLP-1/GIP/glucagon) shows a clear trend toward activating multiple metabolic pathways simultaneously. Each additional target has produced greater weight loss and metabolic benefits.

From Injection to Pill

The race to develop effective oral medications (orforglipron, oral amycretin, the Wegovy pill) reflects patient demand for needle-free options. Within a few years, patients may have a choice between pills that are easy to take and injections that produce maximum results.

From Weight Loss to Metabolic Health

Next-gen drugs are being studied not just for weight loss but for cardiovascular protection, liver disease treatment, kidney protection, osteoarthritis relief, and sleep apnea improvement. The framing is shifting from "weight-loss drugs" to "metabolic health drugs."

From Stigma to Standard of Care

With the obesity drug market projected to hit $150 billion by 2035, pharmaceutical investment at unprecedented levels, and Medicare expanding coverage in 2026, GLP-1 medications are rapidly becoming mainstream medicine rather than a controversial luxury.

---

Frequently Asked Questions

Q: When will retatrutide be available to patients?

Retatrutide's first successful Phase 3 trial results were reported in December 2025, but seven additional Phase 3 trials are still underway through 2026. Eli Lilly will need to compile the full Phase 3 data package before submitting to the FDA for approval. Clarivate projects a potential U.S. launch in 2028, but this could shift depending on trial results and the FDA review timeline. Retatrutide is currently only available to participants in clinical trials.

Q: Is orforglipron better than Wegovy or Zepbound?

Orforglipron produces less weight loss on average (~10.5%) compared to injectable Wegovy (~15%) or Zepbound (~21%). Its main advantage is convenience — it is a daily pill with no food or water restrictions, making it the easiest GLP-1 medication to take. For patients who prioritize maximum weight loss, injectable options remain superior. For patients who strongly prefer pills or who struggle with injection adherence, orforglipron could be a better fit.

Q: Will next-gen drugs be cheaper than current options?

Pricing has not been announced for most pipeline drugs, but several factors could put downward pressure on prices. Increased competition (more drugs on the market), Medicare price negotiations (Ozempic, Wegovy, and Rybelsus are in the second round of Medicare negotiations with new prices effective in 2027), and the availability of generic and biosimilar versions of older GLP-1 drugs could all contribute to lower costs over time.

Q: Can I participate in a clinical trial for these drugs?

Yes. Clinical trials for retatrutide, amycretin, survodutide, and MariTide are actively enrolling participants. You can search for available trials at ClinicalTrials.gov by searching for the drug name. Most trials require participants to have a BMI of 30+ (or 27+ with a comorbidity) and to meet specific health criteria. Participants typically receive the medication for free during the trial.

Q: What is the most promising next-gen GLP-1 drug?

This depends on what you value most. For maximum weight loss, retatrutide (28.7% in Phase 3) is the clear leader. For convenience, orforglipron (no-restriction daily pill) is unmatched. For patients already on semaglutide who want better results, CagriSema (22.7%) offers a direct upgrade. For speed of weight loss, amycretin's 22% in just 36 weeks is remarkable. Each drug has a different strength, and the "best" choice will depend on individual patient needs and preferences.

---

This article is for informational purposes only and does not constitute medical advice. The drugs discussed in this article (except where noted) are investigational and not yet approved by the FDA for general use. Clinical trial results may not reflect real-world outcomes. Always consult your healthcare provider for personalized medical advice.

-- The GLP-1 Daily Team